<DOC>
	<DOC>NCT00689104</DOC>
	<brief_summary>The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.</brief_summary>
	<brief_title>Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Subject is willing and able to complete the micturition diary and questionnaires correctly Subject has symptoms of overactive bladder (urinary frequency and urgency with or without urge incontinence) for ≥ 3 months Subject experiences frequency of micturition on average ≥ 8 times per 24hour period during the 3day micturition diary period Subject must experience at least 3 episodes of urgency (grade 3 or 4) with or without incontinence, during the 3day micturition diary period Subject is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control Subject has significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor Subject has an indwelling catheter or practices intermittent selfcatheterization Subject has diabetic neuropathy Subject has evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs Subject receives nondrug treatment including electrostimulation therapy Subject has severe hypertension Subject has a known or suspected hypersensitivity to tolterodine, other anticholinergics, YM178, other betaadrenoreceptor (ßAR) agonists, or lactose or any of the other inactive ingredients Subject has been treated with any investigational drug or device within 30 days (90 days in the UK) Subject had an average total daily urine volume &gt; 3000 mL as recorded in the 3day micturition diary period Subject has serum creatinine &gt;150 umol/L, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt; 2x upper limit of normal range (ULN), or gamma glutamyl transferase (γGT) &gt; 3x ULN Subject has a clinically significant abnormal electrocardiogram (ECG)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Overactive bladder (OAB)</keyword>
	<keyword>Frequency</keyword>
	<keyword>Micturition</keyword>
	<keyword>Urgency</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>Urinary urge incontinence</keyword>
	<keyword>YM178</keyword>
</DOC>